Spark Biomedical Receives New CMS Codes for Transcutaneous Auricular Neurostimulation (tAN) Therapy
Spark Biomedical, Inc., a frontrunner in non-invasive neurostimulation technology, has been granted two distinct Healthcare Common Procedure Coding System (HCPCS) codes by the Centers for Medicare and Medicaid Services (CMS). These codes pertain to the Sparrow Ascent, the first FDA-cleared non-invasive neurostimulation device designed for opioid withdrawal treatment, as well as its daily-disposable Earpiece Kit. This development is a vital step toward securing insurance coverage, thereby making this groundbreaking treatment more widely available to individuals battling opioid use disorder across the country.
Addressing a Vital Need in Opioid Recovery
The opioid crisis in the United States continues to wreak havoc, resulting in countless overdose deaths every day. Despite the gravity of this situation, many individuals suffering from opioid use disorder do not receive the treatment they need. The new HCPCS codes for Sparrow Ascent signify a major leap forward in enhancing access to effective opioid detox solutions. By utilizing innovative bioelectric medicine, Sparrow Ascent fills essential treatment gaps, allowing those who are unable to leave their homes, jobs, or families to effectively manage this crucial first step toward recovery.
Revolutionizing Treatment through Home-Based Recovery
In response to the urgent need for accessible opioid withdrawal treatment options, CMS's decision positions Sparrow Ascent as the first opioid withdrawal treatment device recognized as durable medical equipment (DME). Effective from a specified date, these codes not only improve the accessibility of opioid withdrawal treatment but also empower individuals to embark on their recovery journey from the comfort of their homes.
Insights from Leadership
Daniel Powell, CEO of Spark Biomedical, shared his thoughts on this significant development, stating, "We are pleased that CMS recognizes the profound impact that The Sparrow Ascent can have on the opioid epidemic, and we are determined to continue to obtain widespread coverage so that every American struggling with opioid addiction can access this life-saving therapy." This statement underscores the company’s commitment to tackling a national health crisis.
Future Directions for Spark Biomedical
Looking ahead, Spark Biomedical is dedicated to utilizing the new HCPCS codes to broaden access to Sparrow Ascent for as many Americans with opioid use disorder as possible. The company will maintain close collaboration with the Centers for Medicare and Medicaid Services to ensure the effective implementation of these codes and to enhance access to Sparrow Ascent. Moreover, Spark Biomedical remains committed to ongoing research and development, pushing the frontiers of innovation in bioelectric medicine, and providing improved options in mental health, women’s health, hemostasis, pediatrics, and chronic pain.
About Spark Biomedical
Spark Biomedical, Inc. is a prominent U.S.-based medical device developer focused on harnessing the potential of bioelectric medicine and introducing novel wearable neurostimulation treatment options in mental health, women’s health, hemostasis, pediatrics, and chronic pain. The company has secured funding from federal institutions and continues to collaborate with private and academic partners. With its expertise in neuroscience and engineering, Spark develops innovative, evidence-based tools aimed at addressing complex care challenges that surpass existing treatment options. Spark Biomedical is paving a new path for the future of patient care and medical technology. For more information, visit sparkbiomedical.com.
For inquiries, please contact Udim Obot at udim.obot@sparkbiomedical.com.
Frequently Asked Questions
What are the new CMS codes for Spark Biomedical?
The new CMS codes cover the Sparrow Ascent device and its daily-disposable Earpiece Kit for non-invasive neurostimulation treatment in opioid withdrawal.
How does Sparrow Ascent aid in opioid withdrawal recovery?
Sparrow Ascent utilizes transcutaneous auricular neurostimulation (tAN) therapy to help manage opioid withdrawal symptoms, allowing individuals to undergo treatment at home.
What impact does this have on insurance coverage?
The issuance of HCPCS codes is a critical step towards securing insurance coverage, making this innovative treatment more accessible to those in need.
What future plans does Spark Biomedical have?
Spark Biomedical plans to expand access to Sparrow Ascent and continue research to innovate in areas such as mental health and chronic pain treatment.
Who is the CEO of Spark Biomedical?
The CEO of Spark Biomedical is Daniel Powell, who is committed to addressing the opioid epidemic and providing accessible treatment options for those affected.
